Insmed Incorporated
Insmed Incorporated develops therapies for serious and rare diseases globally. They offer ARIKAYCE for M. avium complex lung disease as part of a combination antibacterial regimen. Brensocatib is being developed to treat bronchiectasis and other neutrophil-mediated diseases. Treprostinil Palmitil Inhalation Powder treats pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
Overview
Strengths
- Pricing power: gross margin has held between 76% and 80% over the last 6 years (latest 79.7%).
- Consistent growth: revenue has compounded at 29.8% a year over 5 years, rising every year.
- Paying down debt: long-term debt fell by 30.6 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 7.7% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 16.5% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data